Manufacturer with High Purity and Stable Quality
Supply Valsartan and Related Intermediates:
Valsartan CAS: 137862-53-4
L-Valine Methyl Ester Hydrochloride (H-Val-OMe·HCl) CAS: 6306-52-1
| Chemical Name |
Valsartan |
| Synonyms |
N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine |
| CAS Number |
137862-53-4 |
| CAT Number |
RF-API32 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C24H29N5O3 |
| Molecular Weight |
435.52 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White or Off-White Powder; Odourless, Hygroscopic |
| Identification |
IR, HPLC: Must Conform to The Reference Standard |
| Solubility |
Soluble in Methanol and Ethanol, Sparingly Soluble in Ethylacetate, Slightly Soluble in Dichloromethane, Insoluble in Water |
| Moisture (K.F) |
≤1.0% |
| Absorbance (420mm) |
≤0.02% |
| Sulphated Ash |
≤0.10% |
| Heavy Metals |
≤10ppm |
| Related Substances |
|
| D-Valsartan |
≤1.0% (HPLC) |
| Butyryl-Valsartan |
≤0.20% |
| Benzyl-Valsartan |
≤0.10% |
| Single Unknown Inpurity |
≤0.10% |
| Total Impurities |
≤0.30% (excluding D-Valsartan) |
| Residual Solvents |
|
| Methanol |
≤3000ppm |
| Ethyl Acetate |
≤5000ppm |
| N,N-Dimethylformamide |
≤880ppm |
| Toluene |
≤890ppm |
| Assay |
98.0%~102.0% (HPLC) |
| Test Standard |
United States Pharmacopoeia (USP) |
| Usage |
Active Pharmaceutical Ingredient (API) |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Valsartan (CAS: 137862-53-4) with high quality. Valsartan is a nonpeptide angiotensin II AT1 receptor antagonist, Antihypertensive, has the potential for high blood pressure and heart failure research.
Valsartan’s antihypertensive effects are stronger than those of enalapril and is suitable for treating hypertension, mild to moderate primary hypertension, and especially secondary hypertension caused by renal damage. It can significantly reduce proteinuria for hypertension patients with diabetes or normal liver functions, and it can promote uric acid and urinary sodium to protect the kidney. Valsartan is also suitable for reducing the cardiovascular mortality for high risk patients (left ventricular failure or dysfunction) after experiencing a heart attack.